KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Selinexor-Bortezomib-Dexamethasone: A Review in Previously Treated Multiple Myeloma.

Yahiya Y Syed

Target Oncol 18(2) 303-310

PMID36622630
PMCID-
DOI10.1007/s11523-022-00945-3
发表日期2023-01-09
摘要

摘要

Selinexor [Nexpovio® (EU); Xpovio® (USA)] is a first-in-class, selective exportin-1 inhibitor. Oral selinexor once weekly in combination with subcutaneous bortezomib once weekly and oral dexamethasone twice weekly (selinexor-bortezomib-dexamethasone) is approved in the EU and USA for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. In the open-label, randomized, phase 3 BOSTON trial, this regimen significantly prolonged progression-free survival (PFS) compared with the standard bortezomib-dexamethasone regimen in patients with previously treated multiple myeloma. Selinexor-bortezomib-dexamethasone had a generally manageable tolerability profile and an acceptable safety profile in BOSTON, with a lower incidence of peripheral neuropathy (a bortezomib-induced toxicity) compared with bortezomib-dexamethasone. The triplet regimen uses less bortezomib and dexamethasone during the first 24 weeks of treatment. The efficacy and safety profiles of selinexor-bortezomib-dexamethasone, combined with its once-weekly administration of selinexor and bortezomib, make it a useful additional triplet therapy option for previously treated multiple myeloma.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。